Neutropenia - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Neutropenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Neutropenia: Overview
Neutropenia is a blood condition characterized by low levels of neutrophils, which are white blood cells that protect your body from infections. There are four types of neutropenia: Congenital neutropenia, cyclic neutropenia, autoimmune neutropenia, Idiopathic neutropenia. Neutropenia symptoms can range from mild to severe. The lower the level of neutrophils, the more intense the symptoms. Typical symptoms include: fever, pneumonia, sinus infections, otitis media (ear infection), gingivitis (gum inflammation), omphalitis (navel infection) and skin abscesses. Severe congenital neutropenia can have serious symptoms. The symptoms often include bacterial infections. These infections can grow on the skin and in the digestive and respiratory systems. The symptoms of cyclic neutropenia recur in 3-week cycles. Infections can increase when neutrophil levels fall. Neutropenia can be triggered by: chemotherapy, radiation therapy, the use of certain drugs.
Report Highlights
This segment of the Neutropenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Neutropenia Emerging Drugs
In March, 2021, BeyondSpring announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA) for use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).
Romyelocel-L is being developed to prevent bacterial and fungal infections in patients with prolonged neutropenia. Romyelocel-L has been evaluated in three clinical trials to date. In a randomized, controlled Phase 2 trial (NCT02282215), romyelocel-L significantly reduced infections and days in hospital. Romyelocel-L has shown an acceptable safety profile in the three clinical trials, with a total of 151 subjects aged 12 years and above exposed to romyelocel-L.
Further product details are provided in the report
Neutropenia: Therapeutic Assessment
This segment of the report provides insights about the different Neutropenia drugs segregated based on following parameters that define the scope of the report, such as:
Neutropenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Neutropenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neutropenia drugs.
Neutropenia Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Neutropenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Neutropenia: Overview
Neutropenia is a blood condition characterized by low levels of neutrophils, which are white blood cells that protect your body from infections. There are four types of neutropenia: Congenital neutropenia, cyclic neutropenia, autoimmune neutropenia, Idiopathic neutropenia. Neutropenia symptoms can range from mild to severe. The lower the level of neutrophils, the more intense the symptoms. Typical symptoms include: fever, pneumonia, sinus infections, otitis media (ear infection), gingivitis (gum inflammation), omphalitis (navel infection) and skin abscesses. Severe congenital neutropenia can have serious symptoms. The symptoms often include bacterial infections. These infections can grow on the skin and in the digestive and respiratory systems. The symptoms of cyclic neutropenia recur in 3-week cycles. Infections can increase when neutrophil levels fall. Neutropenia can be triggered by: chemotherapy, radiation therapy, the use of certain drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Neutropenia R&D. The therapies under development are focused on novel approaches for Neutropenia.
This segment of the Neutropenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Neutropenia Emerging Drugs
- Plinabulin: BeyondSpring Pharmaceuticals
In March, 2021, BeyondSpring announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA) for use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).
- Romyelocel-L: Cellerant Therapeutics
Romyelocel-L is being developed to prevent bacterial and fungal infections in patients with prolonged neutropenia. Romyelocel-L has been evaluated in three clinical trials to date. In a randomized, controlled Phase 2 trial (NCT02282215), romyelocel-L significantly reduced infections and days in hospital. Romyelocel-L has shown an acceptable safety profile in the three clinical trials, with a total of 151 subjects aged 12 years and above exposed to romyelocel-L.
Further product details are provided in the report
Neutropenia: Therapeutic Assessment
This segment of the report provides insights about the different Neutropenia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Neutropenia
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Neutropenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Neutropenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neutropenia drugs.
Neutropenia Report Insights
- Neutropenia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Neutropenia drugs?
- How many Neutropenia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Neutropenia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neutropenia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Neutropenia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Tanvex Biopharma
- Enzychem Lifesciences
- BeyondSpring Pharmaceuticals
- Mabwell (Shanghai) Bioscience
- Emendo biotherapeutics
- Spectrum Pharmaceuticals
- Cellerant Therapeutics
- X4 Pharmaceuticals
- TX-04
- EC-18
- Plinabulin
- MW05
- EMD-101
- Eflapegrastim
- Romyelocel-L
- Mavorixafor
Introduction
Executive Summary
Neutropenia : Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Neutropenia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Neutropenia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Neutropenia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Romyelocel-L: Cellerant Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
EC-18: Enzychem Lifesciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
TX-04: Tanvex Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Neutropenia Key Companies
Neutropenia Key Products
Neutropenia- Unmet Needs
Neutropenia- Market Drivers and Barriers
Neutropenia- Future Perspectives and Conclusion
Neutropenia Analyst Views
Neutropenia Key Companies
Appendix
Executive Summary
Neutropenia : Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Neutropenia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Neutropenia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Neutropenia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Romyelocel-L: Cellerant Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
EC-18: Enzychem Lifesciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
TX-04: Tanvex Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Neutropenia Key Companies
Neutropenia Key Products
Neutropenia- Unmet Needs
Neutropenia- Market Drivers and Barriers
Neutropenia- Future Perspectives and Conclusion
Neutropenia Analyst Views
Neutropenia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Neutropenia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Neutropenia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Neutropenia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Neutropenia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
